Evolent Health (NYSE:EVH) Coverage Initiated at Needham & Company LLC

Research analysts at Needham & Company LLC assumed coverage on shares of Evolent Health (NYSE:EVH) in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage set a “buy” rating and a $15.00 price target on the technology company’s stock. Needham & Company LLC’s target price would indicate a potential upside of 19.33% from the company’s current price.

A number of other brokerages have also recently weighed in on EVH. JPMorgan Chase & Co. dropped their price target on Evolent Health from $45.00 to $15.00 and set an “overweight” rating on the stock in a research report on Friday, November 22nd. Oppenheimer dropped their price target on Evolent Health from $34.00 to $28.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. Citigroup dropped their price target on Evolent Health from $33.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. BTIG Research dropped their price target on Evolent Health from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, December 3rd. Finally, KeyCorp started coverage on Evolent Health in a research report on Friday, October 11th. They set an “overweight” rating and a $35.00 price target on the stock. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Evolent Health has an average rating of “Buy” and a consensus price target of $23.92.

Evolent Health Trading Down 0.2 %

NYSE:EVH opened at $12.57 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The business’s 50 day moving average is $12.91 and its two-hundred day moving average is $21.03. Evolent Health has a 52 week low of $10.53 and a 52 week high of $35.00. The company has a market cap of $1.47 billion, a PE ratio of -13.81 and a beta of 1.45.

Institutional Trading of Evolent Health

Several large investors have recently added to or reduced their stakes in the business. Quarry LP acquired a new position in shares of Evolent Health during the 2nd quarter valued at $32,000. Covestor Ltd increased its position in shares of Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC increased its position in shares of Evolent Health by 5,365.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after purchasing an additional 1,556 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Evolent Health during the 2nd quarter valued at $61,000. Finally, Quest Partners LLC acquired a new position in shares of Evolent Health during the 2nd quarter valued at $87,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.